Ph.D., Chief Executive Officer, PreCyte, Inc.
Robert Lipshutz is the CEO and founder of PreCyte, an early stage company developing diagnostics for neurodegenerative diseases and cancer. Prior to PreCyte, he was the CBO at the Institute for Systems Biology in Seattle and Senior Vice President Corporate Development at Affymetrix, a biotechnology company developing genomic tools where he developed and launched the first FDA approved microarray based diagnostic tests. He has served as business advisor to Phytelligence, uBiome, and Neurometrix. He was a member of the NRC Board on Mathematics and its Applications. Prior to Affymetrix he was an SVP at Wagner Associate, a consulting firm in mathematics and operations research. He received his Ph.D. from U.C. Berkeley, and his A.M. and B.A. from Harvard University.
PreCyte is developing the Indicator Cell Assay Platform (iCAP), a broadly applicable and inexpensive platform for blood-based diagnostics that can be used for the early detection of disease, and as a companion diagnostic for drug development.